You raise a good point. Pricing of the new oral anticoagulants will cause a dilemma for the sponsors of these drugs when they are approved in multiple indications with different durations of treatment and different competitors (e.g. warfarin in AF; Lovenox in VTE prevention following hip/knee surgery).
When the dust settles, however, I expect generic Lovenox to have a lower copayment than the new oral agents for most patients who receive these drugs for VTE prevention following hip/knee surgery. Hence, I don’t think my estimates of 20% share loss for Lovenox during these patients' pre-discharge period and 60% loss during their post-discharge period (paragraph A in #msg-64848575) are unduly bullish for MNTA.
Market Data 
Markets 
AI
